Article Text

Download PDFPDF
Original article
Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis
  1. Patrice Cacoub1,2,3,4,
  2. Anne Claire Desbois1,2,3,4,
  3. Cloe Comarmond1,2,3,4,
  4. David Saadoun1,2,3,4
  1. 1 Sorbonne Universités, UPMC Univ Paris, Paris, France
  2. 2 Inflammation–Immunopathology–Biotherapy Department, DHU i2B, Paris, France
  3. 3 INSERM, UMRS 959, Paris, France
  4. 4 Department of Internal Medicine and Clinical Immunology, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
  1. Correspondence to Professor Patrice Cacoub, Department of Internal Medicine and Clinical Immunology, AP-HP, Hôpital La Pitié-Salpêtrière, F-75013, Paris, France; patrice.cacoub{at}aphp.fr

Footnotes

  • Contributors Concept and design: PC, ACD, CC, DS. Procedures: PC, ACD, CC, DS. Writing of article: PC, DS.

  • Funding This work was supported by WHO and UNITAID. Main results were presented at the WHO meeting of the Guidelines Development Group for the Hepatitis C Treatment (Geneva, Switzerland, September 2017). It was also supported by an unrestricted grant from Gilead.

  • Competing interests PC has received consulting and lecturing fees from Abbvie, Astra Zeneca, Bristol-Myers Squibb, Gilead, Glaxo Smith Kline, Janssen, Merck Sharp Dohme, Roche, Servier and Vifor. PC has received grants from CNRS, INSERM, Université Pierre et Marie Curie, ANRS and WHO. DS has received consulting and lecturing fees from Medimmune, Abbvie, Bristol Meyer Squibb, Roche, Servier, Gilead, AstraZeneca and GlaxoSmithKline.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors Concept and design: PC, ACD, CC, DS. Procedures: PC, ACD, CC, DS. Writing of article: PC, DS.

  • Funding This work was supported by WHO and UNITAID. Main results were presented at the WHO meeting of the Guidelines Development Group for the Hepatitis C Treatment (Geneva, Switzerland, September 2017). It was also supported by an unrestricted grant from Gilead.

  • Competing interests PC has received consulting and lecturing fees from Abbvie, Astra Zeneca, Bristol-Myers Squibb, Gilead, Glaxo Smith Kline, Janssen, Merck Sharp Dohme, Roche, Servier and Vifor. PC has received grants from CNRS, INSERM, Université Pierre et Marie Curie, ANRS and WHO. DS has received consulting and lecturing fees from Medimmune, Abbvie, Bristol Meyer Squibb, Roche, Servier, Gilead, AstraZeneca and GlaxoSmithKline.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles